A Novel Antibody Humanization Method Based on Epitopes Scanning and Molecular Dynamics Simulation
暂无分享,去创建一个
Lu-lu Gong | You-Wen He | Bin Zhao | Tian-Tian Wang | Tian-tian Wang | Wen-Jing Jin | Cai-Feng Chen | Xiao-Hui Yuan | Ding Zhang | Jing-Jun Liu | You-Wen He | Ding Zhang | Cai-Feng Chen | Bin-Bin Zhao | Lu-Lu Gong | Wen-Jing Jin | Jing-Jun Liu | Jing-Fei Wang | Xiao-Hui Yuan | Jing-fei Wang
[1] A R Rees,et al. Comparison of surface accessible residues in human and murine immunoglobulin Fv domains. Implication for humanization of murine antibodies. , 1994, Journal of molecular biology.
[2] Alexander D. MacKerell,et al. Development and current status of the CHARMM force field for nucleic acids , 2000, Biopolymers.
[3] J. Tjandra,et al. Development of human anti‐murine antibody (HAMA) response in patients , 1990, Immunology and cell biology.
[4] J Saldanha,et al. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. , 1991, Protein engineering.
[5] V. Vyas,et al. Homology Modeling a Fast Tool for Drug Discovery: Current Perspectives , 2012, Indian journal of pharmaceutical sciences.
[6] Gerrit Groenhof,et al. GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..
[7] Lu-lu Gong,et al. Structure-Based High-Throughput Epitope Analysis of Hexon Proteins in B and C Species Human Adenoviruses (HAdVs) , 2012, PloS one.
[8] Lisa Yan,et al. LOOPER: a molecular mechanics-based algorithm for protein loop prediction. , 2008, Protein engineering, design & selection : PEDS.
[9] A. Lew,et al. Rapid specific amplification of rat antibody cDNA from nine hybridomas in the presence of myeloma light chains. , 2006, Journal of immunological methods.
[10] S L Morrison,et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[11] Deping Wang,et al. Structure-Guided Design of Antibodies. , 2010, Current computer-aided drug design.
[12] P. T. Jones,et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.
[13] M. Nussenzweig,et al. DEC-205 is a cell surface receptor for CpG oligonucleotides , 2012, Proceedings of the National Academy of Sciences.
[14] P. Kollman,et al. Molecular Dynamics Simulations on Solvated Biomolecular Systems: The Particle Mesh Ewald Method Leads to Stable Trajectories of DNA, RNA, and Proteins , 1995 .
[15] Patrick G. Swann,et al. Considerations for the development of therapeutic monoclonal antibodies. , 2008, Current opinion in immunology.
[16] M F del Guercio,et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.
[17] Morten Nielsen,et al. Peptide binding predictions for HLA DR, DP and DQ molecules , 2010, BMC Bioinformatics.
[18] Ran Friedman,et al. Molecular modelling and simulations in cancer research. , 2013, Biochimica et biophysica acta.
[19] G. Forbes. Molecular Dynamics , 1885, Nature.
[20] J. Reichert,et al. Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.
[21] R. Poljak,et al. The three-dimensional structure of the fab' fragment of a human myeloma immunoglobulin at 2.0-angstrom resolution. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[22] Pablo G Debenedetti,et al. A computational investigation of thermodynamics, structure, dynamics and solvation behavior in modified water models. , 2008, The Journal of chemical physics.
[23] T. Waldmann,et al. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin , 1989, Nature.
[24] W. Heath,et al. DEC-205 is a cell surface receptor for CpG oligonucleotides , 2013, Oncoimmunology.
[25] Yanhong Tang,et al. Molecular modeling and epitopes mapping of human adenovirus type 3 hexon protein. , 2009, Vaccine.
[26] Liangji Zhou,et al. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[27] M. Suyama,et al. Comparison of protein structures using 3D profile alignment , 2009, Journal of Molecular Evolution.
[28] Shufeng Zhou,et al. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening. , 2012, Current pharmaceutical biotechnology.
[29] W. Mandecki,et al. Recombinant Mouse-Human Chimeric Antibodies as Calibrators in Immunoassays That Measure Antibodies toToxoplasma gondii , 1998, Journal of Clinical Microbiology.
[30] G. A. Lazar,et al. A molecular immunology approach to antibody humanization and functional optimization. , 2007, Molecular immunology.
[31] Jeffrey J. Gray,et al. Toward high‐resolution homology modeling of antibody Fv regions and application to antibody–antigen docking , 2009, Proteins.
[32] W. G. Hoover. molecular dynamics , 1986, Catalysis from A to Z.
[33] Leonard G Presta,et al. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. , 2006, Advanced drug delivery reviews.
[34] A R Rees,et al. A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing. , 1996, Protein engineering.
[35] Begoña Calvo,et al. Therapeutic monoclonal antibodies: strategies and challenges for biosimilars development. , 2012, Current medicinal chemistry.
[36] R. Poljak,et al. The Three-Dimensional Structure of the Fab′ Fragment of a Human Myeloma Immunoglobulin at 2.0-Å Resolution , 1974 .
[37] V. Giudicelli,et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. , 2003, Developmental and comparative immunology.
[38] Alessandra Nurisso,et al. A practical introduction to molecular dynamics simulations: applications to homology modeling. , 2012, Methods in molecular biology.
[39] Janice M. Reichert,et al. Marketed therapeutic antibodies compendium , 2012, mAbs.
[40] L. Presta,et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[41] E. Padlan,et al. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. , 1991, Molecular immunology.
[42] C. Milstein,et al. Reshaping human antibodies: grafting an antilysozyme activity. , 1988, Science.
[43] John Sidney,et al. A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..
[44] R. Steinman,et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing , 1995, Nature.
[45] R. Steinman,et al. In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.
[46] P. Marlton,et al. Incidence and nature of CD20‐negative relapses following rituximab therapy in aggressive B‐cell non‐Hodgkin's lymphoma: a retrospective review , 2002, British journal of haematology.
[47] K. Dill,et al. Using quaternions to calculate RMSD , 2004, J. Comput. Chem..
[48] J. Thornton,et al. AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR , 1996, Journal of biomolecular NMR.
[49] Rodrigo Lopez,et al. Clustal W and Clustal X version 2.0 , 2007, Bioinform..